What is HC Wainwright's Estimate for SPTX FY2026 Earnings?

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Seaport Therapeutics to ($3.95) from ($4.09), versus a consensus estimate of ($4.39).
• The firm maintained a Buy rating and a $50 price target. Analysts’ average rating is “Moderate Buy,” with a consensus price target of $37.12.
• Seaport reported quarterly EPS of ($0.49), beating the consensus estimate of ($0.58) by $0.09.

Seaport Therapeutics, Inc. (NASDAQ:SPTX - Free Report) - Equities researchers at HC Wainwright increased their FY2026 earnings per share estimates for shares of Seaport Therapeutics in a research note issued to investors on Wednesday, November 4th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($3.95) for the year, up from their prior estimate of ($4.09). HC Wainwright currently has a "Buy" rating and a $50.00 price objective on the stock. The consensus estimate for Seaport Therapeutics' current full-year earnings is ($4.39) per share. HC Wainwright also issued estimates for Seaport Therapeutics' Q4 2026 earnings at ($0.53) EPS, Q1 2027 earnings at ($0.61) EPS, Q3 2027 earnings at ($0.69) EPS, Q4 2027 earnings at ($0.71) EPS and FY2027 earnings at ($2.65) EPS.

A number of other research analysts have also recently issued reports on the company. Seaport Research Partners set a $28.00 target price on Seaport Therapeutics in a research report on Wednesday, October 14th. JPMorgan Chase & Co. increased their target price on shares of Seaport Therapeutics from $40.00 to $41.00 and gave the stock an "overweight" rating in a report on Thursday. Weiss Ratings upgraded shares of Seaport Therapeutics from a "sell (d)" rating to a "sell (d+)" rating in a research note on Wednesday. Raymond James Financial initiated coverage on shares of Seaport Therapeutics in a research note on Friday, September 25th. They issued a "strong-buy" rating and a $46.00 price target on the stock. Finally, UBS Group reaffirmed a "buy" rating on shares of Seaport Therapeutics in a report on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Seaport Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $37.12.

Seaport Therapeutics Stock Down 2.7%

Shares of SPTX stock opened at $20.39 on Friday. The stock's fifty day simple moving average is $20.77. Seaport Therapeutics has a twelve month low of $14.85 and a twelve month high of $28.38.

Seaport Therapeutics (NASDAQ:SPTX - Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.09.

Hedge Funds Weigh In On Seaport Therapeutics

Several large investors have recently bought and sold shares of SPTX. HighTower Advisors LLC bought a new stake in shares of Seaport Therapeutics during the second quarter worth about $362,000. Squarepoint Ops LLC acquired a new position in shares of Seaport Therapeutics in the second quarter valued at approximately $538,000. State Street Corp acquired a new position in shares of Seaport Therapeutics in the second quarter valued at approximately $1,448,000. Alps Advisors Inc. raised its holdings in Seaport Therapeutics by 30.5% in the 3rd quarter. Alps Advisors Inc. now owns 70,921 shares of the company's stock valued at $1,430,000 after buying an additional 16,593 shares during the last quarter. Finally, Alyeska Investment Group L.P. bought a new position in Seaport Therapeutics in the 2nd quarter valued at approximately $1,629,000.

Insider Activity at Seaport Therapeutics

In other news, Director Denice Torres acquired 5,000 shares of the business's stock in a transaction that occurred on Tuesday, November 3rd. The shares were bought at an average price of $19.86 per share, with a total value of $99,300.00. Following the acquisition, the director directly owned 5,000 shares in the company, valued at $99,300. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink.

About Seaport Therapeutics

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for central nervous system (CNS) disorders. The company uses its Glyph platform, a technology designed to create prodrugs that may improve the delivery, tolerability, and effectiveness of certain therapies, including treatments intended to reach the brain.

Seaport's pipeline includes investigational therapies for neurological and neuropsychiatric conditions. Its programs have included GTX-102, an oral investigational medicine being developed for Angelman syndrome, a rare genetic neurodevelopmental disorder, as well as additional candidates aimed at addressing unmet needs in CNS care.

The company was established with support from PureTech Health and is headquartered in Boston, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.